RUBCN and metabolic dysfunction-associated steatotic liver disease: The silence of Rubicon upregulates the levels of phosphatidylcholine and phosphatidylethanolamine and reduces CD36 expression, indicating the therapeutic potential of Rubicon blockage for NAFLD.